(Reuters)Cincinnati-based Medpace Holdings Inc, a clinical contract research organization focused on the biotech, pharmaceutical and medical device sectors, has raised $161 million for its IPO after pricing its 7 million shares at $23 per share. The stock began trading August 11 on the NASDAQ under the ticker symbol “MEDP.” Jefferies LLC and Credit Suisse Securities (USA) LLC are serving as the lead underwriters. Medpace is backed by Cinven.
PRESS RELEASE
CINCINNATI–(BUSINESS WIRE)–Aug. 10, 2016– Medpace Holdings, Inc. (“Medpace”) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share. All of the shares of common stock are being offered by Medpace. In addition, Medpace has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock from Medpace at the initial public offering price, less underwriting discounts and commissions. Medpace’s common stock is expected to begin trading on the NASDAQ Global Select Market on August 11, 2016 under the ticker symbol “MEDP,” and the offering is expected to close on August 16, 2016, subject to customary closing conditions.
Medpace intends to use the net proceeds of this offering to repay a portion of its outstanding borrowings under its senior secured term loan facility.
Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint lead book-running managers for the offering. UBS Securities LLC and Wells Fargo Securities, LLC are also acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated and William Blair & Company, L.L.C. are acting as co-managers for the offering.
The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting:
Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, via telephone: 1-877-547-6340, or via email: Prospectus_Department@Jefferies.com; or
Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, Eleven Madison Avenue, New York, NY 10010, via telephone: 1-800-221-1037, or via email: newyork.prospectus@credit-suisse.com.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About Medpace
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people across 35 countries.
Blogger Comment
Facebook Comment